title: Reply to "A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned".
authors.forename: John R
authors.initials: JR
authors.lastname: Dimar
authors.forename: Steven D
authors.initials: SD
authors.lastname: Glassman
authors.forename: J Kenneth
authors.initials: JK
authors.lastname: Burkus
authors.forename: Philip W
authors.initials: PW
authors.lastname: Pryor
authors.forename: James W
authors.initials: JW
authors.lastname: Hardacker
authors.forename: Leah Y
authors.initials: LY
authors.lastname: Carreon
mesh_terms: D055396:Bone Morphogenetic Protein 2 / Q000009:adverse effects*; D002986:Clinical Trials as Topic / Q000592:standards*; D016265:Conflict of Interest; D006801:Humans; D012107:Research Design / Q000592:standards*; D013123:Spinal Fusion / Q000379:methods*; D016212:Transforming Growth Factor beta / Q000009:adverse effects*
chemical_list: D055396:Bone Morphogenetic Protein 2; D016212:Transforming Growth Factor beta